Suzhou Ribo Life Science Receives Phase II Trial Approval for RBD5044 in China
I'm PortAI, I can summarize articles.
Suzhou Ribo Life Science Co., Ltd. has received approval from China's National Medical Products Administration to advance its RBD5044 Injection into Phase II clinical trials. This siRNA therapy targets APOC3, a protein linked to lipid metabolism, and aims to treat complications from hypertriglyceridemia. However, the company cautions that successful development and commercialization are not guaranteed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments